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Introduction
Dengue virus (DENV) is the most prevalent mosquito-borne virus causing disease in humans (1), with an 
estimated 390 million annual infections worldwide, of  which 96 million manifest with clinical symptoms 
(2). Dengue disease may present as a nonspecific febrile illness or as a more severe infection marked by 
hemorrhage or circulatory failure (3, 4). DENV is a flavivirus that exists as 4 distinct serotypes (DENV-1–
DENV-4) and is transmitted by Aedes mosquitoes (5). At the amino acid level, the 4 DENV serotypes share 
limited similarity among serotypes (about 60%–75%) but about 97% similarity within a given serotype (6). 
Epidemiological studies have reported differences between serotypes with regard to disease severity. Nota-
bly, DENV-2 secondary infections have been associated with more severe disease, while DENV-4 infections 
have been correlated with more mild disease (7–12).
Hematopoietic cells of  the myeloid lineage, such as monocytes, macrophages, and DCs, are the prima-
ry targets of  DENV infection, replication, and dissemination (13–21). Immature DCs in the periphery effi-
ciently capture antigens via phagocytosis and macropinocytosis. Upon interacting with infectious agents, 
immature DCs subsequently mature, a process that includes DC surface remodeling, increased antigen 
presentation, and the production of  numerous cytokines (22). Mature DCs upregulate chemokine receptors 
(e.g., CCR7) that aid in their migration to lymph nodes as well as costimulatory molecules (e.g., CD80, 
CD86, CD40) that are required for activating antigen-specific T cells in the lymph node and inducing T cell 
proliferation and effector functions (23, 24). In this way, DCs are key players in linking innate and adaptive 
immunity. Therefore, the ability of  viruses to modulate innate immunity in these cells will have a signifi-
cant affect on viral replication, dissemination, and pathogenesis.
Peripheral blood mononuclear cells from healthy blood donors can be used to generate monocyte- 
derived DCs. These cells can be productively infected with DENV and are the primary human ex vivo 
Dengue virus (DENV) is the most prevalent mosquito-borne virus causing human disease. Of the 
4 DENV serotypes, epidemiological data suggest that DENV-2 secondary infections are associated 
with more severe disease than DENV-4 infections. Mass cytometry by time-of-flight (CyTOF) 
was used to dissect immune changes induced by DENV-2 and DENV-4 in human DCs, the initial 
targets of primary infections that likely affect infection outcomes. Strikingly, DENV-4 replication 
peaked earlier and promoted stronger innate immune responses, with increased expression of DC 
activation and migration markers and increased cytokine production, compared with DENV-2. In 
addition, infected DCs produced higher levels of inflammatory cytokines compared with bystander 
DCs, which mainly produced IFN-induced cytokines. These high-dimensional analyses during 
DENV-2 and DENV-4 infections revealed distinct viral signatures marked by different replication 
strategies and antiviral innate immune induction in DCs, which may result in different viral fitness, 
transmission, and pathogenesis.
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model for studying primary DENV infections and investigating the effects of  DENV infection on DC 
activation and function (16, 17, 25).
Cytokine production during DENV infection has been observed in patients and in vitro (26). Nev-
ertheless, the pathogenic versus protective roles of  cytokines during DENV infection are not completely 
understood. It has been proposed that a “cytokine storm” results in increased vascular permeability and 
more severe disease (27). However, there are conflicting reports as to whether the Th1 cytokines IFN-γ 
and TNF-α as well as the regulatory cytokines IL-10 and TGF-β promote pathogenesis or confer protec-
tion during DENV infection (28–30). Additionally, our group and others have demonstrated that DENV-2 
(strain 16681) inhibits both type I IFN (IFN-α/β) production and signaling and impairs CD4+ T cell polar-
ization (16, 17, 25, 31–33), which may prevent protective adaptive immune responses.
In this study, we have utilized mass cytometry by time-of-flight (CyTOF) to investigate the effects of  
DENV infection on human DCs. Unlike flow cytometry, which requires compensation for overlapping flu-
orescence spectra, CyTOF uses antibodies labeled with elemental isotopes and is largely unencumbered by 
interference from spectral overlap between channels (34). Currently, CyTOF allows for single-cell analysis 
for up to 45 parameters simultaneously (35). With this powerful technology, which has not yet been used to 
characterize infection with DENV or other hemorrhagic fever viruses, we have simultaneously investigated 
DENV infection, DC activation, intracellular cytokine production, and apoptosis as well as the differences 
between bystander and infected cells in the same DC culture. Importantly, investigating viral replication 
and the subsequent host innate immune responses will provide insight into fitness strategies used by vec-
tor-borne viruses like DENV to remain in circulation, while inducing varying degrees of  disease severity in 
humans. Herein, we provide a comprehensive functional analysis comparing DC infections with DENV-2 
and its most phylogenetically distant serotype, DENV-4, which have been associated with differences in 
disease severity. We show that DENV-2 and DENV-4 display different replication strategies and induce 
different antiviral innate immune responses in human DCs, which may be related to differences in viral 
fitness, transmission, and pathogenesis.
Results
Replication differences between DENV-2 and DENV-4. In this study, we infected human donor-matched DCs 
with DENV-2 and DENV-4 (MOI of  0.5). The viral isolates used were representative of  prevalent geno-
types of  the DENV-2 and DENV-4 serotypes (Supplemental Figures 1 and 2; supplemental material avail-
able online with this article; https://doi.org/10.1172/jci.insight.92424DS1). Using CyTOF analysis to 
measure intracellular DENV structural and nonstructural proteins and titration of  extracellular infectious 
DENV particles, we found that DENV-2 peak infection occurred at 48 hours after infection (hpi), whereas 
DENV-4 infection peaked at 24 hpi and was significantly diminished by 72 hpi (Figure 1, A–D). Notably, 
DENV-4 infection resulted in a greater percentage of  infected DCs compared with DENV-2 infection (Fig-
ure 1, A and B). Interestingly, despite significant differences in the percentages of  infected cells (Figure 1B) 
and different infection kinetics (Figure 1D), the peak titers of  infectious particles released extracellularly 
were similar between DENV-2 and DENV-4 (Figure 1D). Additionally, even though DENV-2 infected a 
smaller percentage of  cells compared with DENV-4, those DCs infected with DENV-2 showed significantly 
higher levels of  DENV nonstructural 3 (NS3) protein (Figure 1C) at 48 and 72 hpi compared with the DCs 
infected with DENV-4. Together, these data suggest that DENV-2 infects fewer DCs later during infection, 
with each infected cell producing many infectious particles, whereas DENV-4 infects more DCs earlier 
during infection, with each infected cell producing fewer infectious particles.
We also compared DENV-2 and DENV-4 replication kinetics in mosquito cells. Using Aag2 cells (an 
Aedes aegypti cell line), we observed comparable replication kinetics for DENV-2 and DENV-4 during a 
5-day time course (Figure 1E). In particular, the rapid peak and subsequent decline in titers for DENV-4 
during DC infection was not observed in mosquito cells. Thus, these viruses have different replication 
kinetics, and presumably different viral fitness strategies, in human DCs but not in mosquito cells.
Differential effects of  DENV-2 and DENV-4 infection on DC phenotype and function. To fully appreciate 
DC phenotype and function during DENV infection, three distinct yet complementary techniques were 
employed to analyze the CyTOF data: (a) a global view of  the DC phenotype was demonstrated by heat 
maps utilizing an autogating strategy (36, 37) (Figure 2 and Supplemental Figure 3B); (b) multiple DC 
donors were compared via a manual gating scheme (Supplemental Figure 3A and Supplemental Figures 
4–6); and (c) single-cell data were illustrated with viSNE analysis (Figure 3 and Supplemental Figure 7). 
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With these analyses, it was apparent that DC infection with DENV-2 or DENV-4 led to significant upregu-
lation of  DC activation markers CD80 and CD40 as well as cytokines and chemokines (i.e., TNF-α, IL-1β, 
IL-8, and IP-10) compared with mock treatment (Figure 2, A and B; Figure 3; and Supplemental Figures 
4, 5, and 7). Additionally, DENV-4 infection, but not DENV-2 infection, led to the upregulation of  DC 
migration marker CCR7 compared with mock treatment (Figure 2, A and B; Figure 3; and Supplemental 
Figures 4 and 7). Strikingly, we found that DENV-4 infection induced higher expression of  CD80, CD40, 
and CCR7 and greater production of  TNF-α+, IL-1β+, and IL-8+ cells when compared with DENV-2 infec-
tion (Figure 2C; Figure 3; and Supplemental Figures 4, 5, and 7). Notably, DCs infected with DENV-2 
and DENV-4 did not demonstrate statistically significant differences in expression of  cleaved caspase-3, a 
marker for apoptosis, or in levels of  cell death (Supplemental Figure 6) (38).
Additionally, with viSNE analysis of DENV-4 infection, it was notable that there were clusters of cells 
expressing high levels of DENV envelope (DENV E) protein, but these cells were not limited to one phenotypic 
Figure 1. DENV-2 and DENV-4 demonstrate replication differences in human DCs but not in mosquito cells. (A) Mass cytometry by time-of-flight (CyTOF) 
analysis of DCs infected at an MOI of 0.5 with dengue virus 2 (DENV-2) and DENV-4. Viral infection was visualized by antibody staining for the DENV enve-
lope (DENV E) and nonstructural 3 (NS3) proteins. DENV-infected cells were gated on live single CD45+ cells. One representative donor of seven is shown. 
(B) The percentage of DENV-infected DCs was quantified as shown in A by CyTOF analysis for all 7 donors. (C) Mean signal intensity of DENV NS3 protein 
staining for cells positive for DENV infection for all 7 donors. (D) Replication kinetics of DENV-2 and DENV-4 in DCs, as determined by plaque assay of 
extracellular infectious particles. Fifteen donors are represented. (E) Replication kinetics of DENV-2 and DENV-4 (MOI of 0.5) in Aag2 cells, as determined 
by plaque assay of extracellular infectious particles. The graph depicts 3 biological replicates. Mean ± SEM is shown. Black asterisks represent statistical 
significance by the paired, 2-tailed Wilcoxon signed-rank test, comparing DENV-4 to DENV-2 at each time point. Red asterisks represent statistical signif-
icance for either DENV-2 or DENV-4 compared with mock-infected cells at each time point. The Benjamini-Hochberg procedure was performed within each 
time point to adjust the significance level for multiple comparisons (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001).
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DC population (Figure 3 and Supplemental Figure 7B). Interestingly, cells expressing high levels of TNF-α and 
IL-1β corresponded with a cluster of DENV E–expressing cells (Figure 3 and Supplemental Figure 7B). IL-8 
expression was more broadly distributed but also largely colocalized to the same region of the viSNE plots 
(Figure 3 and Supplemental Figure 7B). In contrast, cells most highly expressing IP-10 did not correspond with 
DENV E–expressing cells (Figure 3). During the peak of DENV-2 infection, a small number of cells expressing 
high levels of DENV E were visible but distributed throughout the viSNE plots (Figure 3 and Supplemental Fig-
ure 7B). In addition, TNF-α, IL-1β, IP-10, and IL-8 were notably upregulated in DCs during DENV-2 infection 
compared with mock treatment (Figure 3 and Supplemental Figure 7).
Interestingly, DC costimulatory markers CD80, CD86, and CD40 as well as the DC migration mark-
er CCR7 displayed an entirely different pattern, with cells expressing high levels of  these markers being 
localized to distinct regions of  the plots from those expressing high levels of  cytokines; this was most clear 
during later time points of  DENV-4 infection (Figure 3 and Supplemental Figure 7B). This indicates that 
the cells upregulating cytokines are distinct from those upregulating high levels of  DC maturation markers 
during DENV infection. This was consistent with the hierarchical clustering analysis of  autogated CyTOF 
data (Figure 2), in which cytokines clustered more closely to DENV antigens and other cytokines and far-
ther from DC phenotypic and functional markers. Additionally in viSNE analysis, the cells expressing high 
levels of  cleaved caspase-3, a marker for apoptosis, were largely localized to a distinct cluster, representing 
another distinct group of  cells responding to DENV infection (Figure 3 and Supplemental Figure 7). Alto-
gether, these data indicated that the responses to DENV infection in these DC cell cultures were heteroge-
neous and that there were distinct cellular phenotypes associated with cells expressing viral antigens.
Figure 2. Comparing cellular marker positivity during mock, DENV-2, and DENV-4 infections by 
autogating. Heat maps comparing cellular marker positivity by denoting cells as either positive 
or negative for each marker during mock, dengue virus 2 (DENV-2), and DENV-4 infections. For all 
plots, markers are ordered vertically by hierarchical clustering of the rows, which places markers 
with similar expression profiles closer together. Statistical significance was determined using 
a 2-sided Fisher’s exact test at a threshold of α = 10–5 with Bonferroni correction for multiple 
testing. Cellular markers not representing a significant difference between infection conditions at 
this threshold are labeled with “NS”; all others are significant. Calculations were made using the 
event counts from mass cytometry by time-of-flight (CyTOF) data, as determined by autogating 
of cells positive for each marker based on the 99th percentile threshold, which was set for mock 
treatment at 8 hours after infection (hpi). The comparative effects on each marker were calculated 
as the log10 of the relative risk for positive marker frequency between the indicated infection con-
ditions. The histograms within the heat map color scales show the total number of cells matching 
that intensity range, revealing the overall distribution of the values. One representative DC donor 
of seven is shown. (A) DENV-2 infection and mock treatment are compared. Red indicates greater 
marker expression during DENV-2 infection, and blue indicates greater marker expression during 
mock treatment. (B) DENV-4 infection and mock treatment are compared. Red indicates greater 
marker expression during DENV-4 infection, and blue indicates greater marker expression during 
mock treatment. (C) DENV-4 and DENV-2 infections are compared. Red indicates greater marker 
expression during DENV-4 infection, and blue indicates greater marker expression during DENV-2 
infection. White indicates no difference in marker expression between the infection conditions.
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Figure 3. The phenotypic 
landscape is different 
during DENV-2 versus 
DENV-4 infection in DCs. 
Live single CD45+ cells from 
representative donor 2 
(Supplemental Figure 3B) 
of the 7 DC donors were 
used to create viSNE plots, 
which were generated using 
all 18 phenotypic markers 
used for mass cytometry 
by time-of-flight (CyTOF) 
staining except markers for 
dengue virus (DENV). Each 
point in the plot represents 
a single cell, and the axes 
show arbitrary units based 
on the t-distributed sto-
chastic neighbor embedding 
(t-SNE) algorithm. The 
relative position of a cell 
on the plot represents its 
general phenotype in mul-
tidimensional space. For 
(A) 24 hours after infection 
(hpi) and (B) 48 hpi, cells 
are colored according to 
staining intensity of the 
indicated marker, enabling 
the comparison of expres-
sion patterns across mark-
ers for different infection 
conditions and time points 
after infection.
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The contribution of  bystander versus infected 
cells during DENV infection. The previous data 
(Figures 2 and 3) revealed marked phenotypic 
differences induced by DENV-2 and DENV-4 
for the entire population of  each DC sample. 
The power of  CyTOF analysis includes the 
possibility of  distinguishing between infect-
ed and bystander cells within a sample. This 
allowed us to interrogate the specific contribu-
tion of  bystander versus DENV-infected cells 
by using markers indicative of  DENV infection 
(i.e., DENV E and NS3 proteins). Notably, the 
various patterns observed between infected 
and bystander cells were similar during both 
DENV-2 and DENV-4 infections. Generally, 
DC activation markers CD80, CD86, CD40, 
and CCR7 were similarly upregulated by 
DENV-infected and bystander cells following 
both DENV-2 and DENV-4 infection of  DC 
cultures (Figure 4). On the other hand, both 
DENV-2–infected and DENV-4–infected DCs 
showed increased production of  TNF-α+ and 
IL-1β+ cells compared with their respective 
bystander cells (Figure 5, A and B). Remark-
ably, this was notable even for DENV-2, despite the low number of  DENV-2–infected cells. IL-8 production 
was generally similar between DENV-infected and bystander cells, except at an early time point when 
DENV-4–infected cells demonstrated a greater percentage of  IL-8+ cells compared with their bystander 
cells (Figure 5C). Interestingly, and consistent with its role as an IFN-stimulated gene (ISG), IP-10 was 
produced primarily by bystander cells compared with DENV-4–infected cells at 24 and 48 hpi, but this 
effect was not as pronounced in DENV-2–infected cultures (Figure 5D). Thus, proinflammatory cytokines 
(TNF-α and IL-1β), chemokines (IL-8), and ISGs (IP-10) demonstrated distinct patterns of  production in 
DENV-infected versus bystander DCs. Additionally, both DENV-2– and DENV-4–infected DCs demon-
strated higher percentages of  cleaved caspase-3+ cells compared with their respective bystander cells at later 
time points, suggesting greater levels of  apoptosis in DENV-infected cells (Figure 5E). It is notable that the 
Figure 4. Bystander cells show similar DC surface 
marker phenotypes compared with infected cells 
during DENV infection. Dengue virus–infected 
(DENV-infected) DCs were gated on live single 
CD45+ cells, as shown in Supplemental Figure 3A. 
Using mass cytometry by time-of-flight (CyTOF) 
analysis for each DENV-2 or DENV-4 sample, the 
cells were stratified as DENV-infected (I) cells 
(filled circles) or bystander (B) cells (open circles). 
Mock-infected cells (M) were analyzed as a single 
population. Seven DC donors are shown. Median 
expression levels of DC surface markers (A) CD80, 
(B) CD86, (C) CD40, and (D) CCR7 for mock, bystand-
er, and DENV-infected cells of DENV-2 (green) and 
DENV-4 (purple) samples are shown. Mean ± SEM is 
shown. Black asterisks represent statistical signifi-
cance by the paired, 2-tailed Wilcoxon signed-rank 
test, comparing bystander and infected cells within 
a given culture sample at a given time point. The 
Benjamini-Hochberg procedure was performed 
within each time point to adjust the significance 
level for multiple comparisons (*P ≤ 0.05).
Downloaded from http://insight.jci.org on July 11, 2017.   https://doi.org/10.1172/jci.insight.92424
7insight.jci.org   https://doi.org/10.1172/jci.insight.92424
R E S E A R C H  A R T I C L E
timing of  these observations is consistent with the 
kinetics of  infection for these two viruses.
Cytokine secretion during DENV-2 versus DENV-
4 infection. In addition to intracellular cytokine 
analyses by CyTOF, multiplex ELISAs were per-
formed to evaluate extracellular cytokine secre-
tion by DCs during DENV infection. Consistent 
with prior results (16, 17, 25, 31, 32, 39, 40), 
DENV-2 infection induced minimal IFN-α and 
low levels of  IP-10 secretion (Figure 6). In con-
trast, DENV-4 infection of  DCs induced greater 
IFN-α and IP-10 secretion compared with mock 
infection and DENV-2 infection of  DCs (Figure 
6). Infection with DENV-4 also induced greater 
secretion of  several proinflammatory cytokines 
and chemokines (i.e., TNF-α, IL-6, IL-1β, IL-12, 
MIP-1α, MIP-1β, RANTES, and IL-8) compared 
with mock and DENV-2 infection (Figure 6). Of  
note, DENV-2 infection induced the secretion of  
several proinflammatory cytokines and chemok-
ines compared with mock infection but to a less-
er extent than DENV-4 infection (Figure 6).
The continuous upregulation of  cytokine 
and chemokine production during DENV-2 
and DENV-4 infection appears to be replica-
tion dependent, since infection of  DCs with 
either UV-inactivated DENV-2 or UV-inactivat-
ed DENV-4, which did not produce infectious 
particles, resulted in lower levels of  cytokine 
and chemokine secretion (e.g., IL-6, TNF-α, 
RANTES, IP-10, MIP-1α, and MIG) at later 
time points compared with infection with their 
respective, replication-competent DENV (Sup-
plemental Figure 8).
Figure 5. Bystander cells show distinct cytokine and 
cleaved caspase-3 phenotypes compared with infected 
cells during DENV infection. Dengue virus–infected 
(DENV-infected) DCs were gated on live single CD45+ 
cells, as shown in Supplemental Figure 3A. Using mass 
cytometry by time-of-flight (CyTOF) analysis for each 
DENV-2 or DENV-4 sample, the cells were stratified 
as DENV-infected (I) cells (filled circles) or bystander 
(B) cells (open circles). Mock-infected cells (M) were 
analyzed as a single population. Seven DC donors 
are shown. The percentage of mock, bystander, or 
DENV-infected cells of DENV-2 (green) and DENV-4 
(purple) samples that stained positive intracellularly for 
the cytokines (A) TNF-α, (B) IL-1β, (C) IL-8, and (D) IP-10 
and for the apoptosis marker (E) cleaved caspase-3 
are shown. Mean ± SEM is shown. Black asterisks 
represent statistical significance by the paired, 2-tailed 
Wilcoxon signed-rank test, comparing bystander and 
infected cells within a given culture sample at a given 
time point. The Benjamini-Hochberg procedure was 
performed within each time point to adjust the signifi-
cance level for multiple comparisons (*P ≤ 0.05).
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The observed differences in cytokine and chemokine production by DENV-2 and DENV-4 could be 
theoretically due to the different proportion of  infected cells in the culture between the two viruses. To 
address this possibility, we infected DCs with DENV-2 and DENV-4 at different MOIs to yield a similar 
percentage of  infected cells at their respective peak titers (Supplemental Figure 9). We found that cyto-
kine and chemokine secretion for DENV-2 infection was generally MOI dependent, with greater cytokine 
and chemokine secretion at the higher MOI (Supplemental Figure 9). Nevertheless, even when DCs were 
infected with DENV-2 at a high MOI of  25, cytokines and chemokines (e.g., IL-6, TNF-α, IL-1β, IL-12, 
RANTES, IP-10, MIP-1α, MIP-1β, and MIG) were still secreted at higher levels during infection with 
DENV-4 (MOI of  0.5) at most time points (Supplemental Figure 9). Together, these data suggest that the 
level of  cytokine and chemokine secretion depended less on viral load (MOI) and more on inherent strain 
differences between the two virus strains.
Discussion
Human immune responses induced by infection with DENV and other hemorrhagic fever viruses are 
complex and characterized by high levels of  proinflammatory cytokines and chemokines. CyTOF allows 
for the simultaneous examination of  viral infection, DC activation, cytokine production, and apoptosis 
for individual cells. In this work, we provide a comprehensive, detailed analysis of  the infection kinetics 
and immune responses induced by DENV-2 and DENV-4 strains in human DCs, which revealed distinct 
viral signatures. To our knowledge, this is the first study to utilize CyTOF to examine cells infected with 
a hemorrhagic fever virus.
Interestingly, these DENV-2 and DENV-4 strains show markedly different replication kinetics in 
human DCs but replicate similarly in mosquito cells (Figure 1). This DENV-4 strain is also more capable 
of  activating human DCs, upregulating DC migration markers, and inducing cytokine production com-
pared with this DENV-2 strain. Therefore, we postulate that DENV-4 may be better adapted for prolonged 
virus replication in mosquitoes compared with human cells, whereas DENV-2 may be well adapted for 
prolonged replication in both hosts. The early burst in DENV-4 replication may be sufficient to produce the 
necessary level of  viremia in the human host to allow for early transmission back to the mosquito before 
the human immune response effectively clears the infection, thereby preventing continuous inflammatory 
responses caused by sustained viral replication. This viral fitness strategy could enable DENV-4 to con-
tinue circulating without causing severe disease in most infected humans. In contrast, the DENV-2 strain 
infects relatively few cells and does not induce such a robust innate immune response in human DCs. In 
this way, DENV-2 may be more efficient than DENV-4 at evading human immune responses, causing a 
more prolonged viremia in the human host and ensuring later transmission back to the mosquito. Addition-
ally, the limited induction of  innate immunity during DENV-2 infection may lead to inefficient adaptive 
immune responses (33) and greater epidemic potential for DENV-2. The data presented in this work there-
by support the epidemiological studies showing that DENV-4 infections generally result in milder disease 
in humans compared with DENV-2 (7–12). Such pronounced differences in immune responses induced by 
these DENV serotypes illustrate the importance of  continued investigation into the unique qualities of  each 
DENV serotype to better characterize DENV-induced immune responses and pathogenesis. Furthermore, 
since the representative DENV strains used in this study were isolated many years ago and have therefore 
undergone numerous passages in the laboratory, future studies will be important for testing multiple strains 
of  these DENV serotypes, including contemporary strains and low-passage human isolates, to further test 
these hypotheses and to minimize the effects of  possible viral adaptations that can occur during passage in 
tissue culture. Additionally, future studies will investigate blood samples from dengue-infected patients to 
correlate virus replication and immune profiles with DENV serotype and disease severity.
There are many differences between these two DENV serotypes that may account for the observed 
differences in replication and immune induction in human cells, which can be tested in future studies. First, 
it has been shown that DENV-4 NS5 is predominantly located in the cytoplasm, whereas DENV-2 NS5 is 
predominantly located in the nuclei of  infected cells (41–43). Since DENV replication takes place in the 
cytoplasm (44), there may be a correlation between the availability of  more NS5 polymerase molecules 
for DENV-4 replication in the cytoplasm and earlier peak replication kinetics. In addition, differences in 
DENV NS5 nuclear localization may affect splicing of  host RNAs, such as those involved in immune 
responses to virus infections (45). Additionally, the most 5′ region of  the DENV 3′ untranslated region 
is one of  the least conserved regions of  the DENV genome among the serotypes (46). Due to differences 
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Figure 6. DENV-4 infection of DCs induces greater cytokine and chemokine secretion compared with DENV-2 infection. Levels of cytokine and 
chemokine secretion (as indicated) were measured by performing multiplex ELISA on supernatants of DC cultures infected with dengue virus 2 
(DENV-2) or DENV-4 (MOI of 0.5) or mock-infected cultures. Sixteen donors are shown. Mean ± SEM is shown. Black asterisks represent statistical 
significance by the paired, 2-tailed Wilcoxon signed-rank test, comparing DENV-4 to DENV-2 at each time point. Red asterisks represent statistical 
significance for either DENV-2 or DENV-4 compared with mock-infected cells at each time point. The Benjamini-Hochberg procedure was performed 
within each time point to adjust the significance level for multiple comparisons (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001).
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in this region, DENV-2 and DENV-4 likely produce different subgenomic flavivirus RNAs (sfRNAs). It 
has been proposed that sfRNA accumulation is associated with viral epidemiological fitness (46, 47). In 
particular, DENV-2 strains with greater sfRNA production relative to viral genomic RNA have been cor-
related with epidemiological fitness (47). It has also been shown that sfRNA can antagonize human innate 
immune pathways, decreasing both IFN and ISG production (48). Furthermore, it was recently found 
that different DENV sfRNA species accumulate in vertebrate and invertebrate hosts during host change, 
with subsequent implications for innate immune responses and viral fitness (49). It would therefore be 
very interesting to determine if  differences in sfRNA could account for differences between DENV-2 and 
DENV-4 with regard to innate immune induction and viral fitness during host adaptation between humans 
and mosquitoes.
Additionally, the viSNE analysis in this study is elucidating because it demonstrates that the DCs pro-
ducing the highest amount of  cytokines are largely distinct from those upregulating the highest amount of  
DC activation markers during DENV infection (Figure 3 and Supplemental Figure 7B). This is consistent 
with hierarchical clustering analysis of  autogated CyTOF data, in which cytokines tend to cluster more 
closely with other cytokines and to DENV antigens and in distinct branches from the DC phenotypic and 
functional markers (Figure 2). This suggests that the expression of  different cytokines may be driven by 
signaling pathways and transcriptional programs that are more similar to one another and less similar to 
those regulating DC surface marker expression following DENV infection.
In addition to comparing the overall effects of  infection by these DENV-2 and DENV-4 strains, 
we also stratified the CyTOF data to quantitatively compare the effects of  DENV on infected cells 
and bystander cells in the same DC cultures. Existing studies have shown some differential effects 
of  DENV-2 infection on bystander cells versus infected cells in the same culture (50–56). Our unique 
CyTOF study using 20 markers simultaneously provides more comprehensive data on changes to DC 
phenotype and function, as well as better temporal resolution, following both DENV-2 and DENV-4 
infections. Consistent with prior data (51, 56), we observed that DCs infected with both DENV-2 and 
DENV-4 strains preferentially produce TNF-α and IL-1β, while bystander DCs preferentially produce 
IP-10 (Figure 5). Interestingly, our data also show that type I IFN is secreted at higher levels during 
DENV-4 infection of  DCs as compared with DENV-2 infection of  DCs (Figure 6). Thus, it is likely that 
DENV-4–infected cells produce type I IFN, which then induces the production of  ISGs, such as IP-10, 
in bystander cells. These bystander cells should be unable to block IFN signaling, since they do not 
contain DENV NS5 protein, which degrades STAT2 in infected cells (31). These data are also in agree-
ment with the literature showing that DENV-2 infections do not induce robust type I IFN responses in 
human DCs (51, 56).
On the other hand, we observed that both DENV-2–infected and DENV-4–infected cells and their 
respective bystander cells upregulate costimulatory molecules compared with mock-infected DCs, which is 
consistent with some prior work with DENV-2 (51, 56). The upregulation in CCR7 observed in our study for 
both infected and bystander cells after DENV-4 infection suggests that both DENV-4–infected and bystander 
DCs could migrate to draining lymph nodes during an in vivo infection. Since we observed that both infected 
and bystander DCs are capable of  activation, the bystander DCs are most likely undergoing cytokine-medi-
ated maturation (51, 52). Of  note, it has been shown that cytokine-induced maturation of  DCs and subse-
quent neoantigen pulsing promotes DC priming of  naive CD4+ T cells toward a Th1 response (23).
Furthermore, we found that DENV-infected cells preferentially undergo apoptosis (as determined 
by cleaved caspase-3 expression) compared with bystander cells at times consistent with viral replication 
during both DENV-2 and DENV-4 infections (Figure 5E). This is consistent with other work showing 
that sustained DENV infection may lead to greater induction of  apoptosis (55). Cells undergoing apop-
tosis may release viral progeny, contributing to virus spreading, or may release apoptotic bodies that are 
later engulfed by other DCs, which may lead to bystander DC maturation. It is also possible that loss of  
DENV-infected DCs by apoptosis could impair the connection between innate and adaptive immunity and 
thereby diminish the human immune response to DENV infection. With these data, we have demonstrat-
ed that both sample-wide and population-stratified analyses are valuable and yield different insights into 
the immunological consequences of  viral infections. Our data clearly demonstrate that DENV infection 
induces important phenotypic changes in both infected and bystander cells, both of  which likely contribute 
to the overall immune response to these viral infections. Furthermore, these data illustrate that even small 
numbers of  DENV-infected cells can contribute to these different responses.
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This work, in concert with previous data in the literature, suggests the following model: dermal DCs 
and Langerhans cells are the primary cells infected with DENV following the bite of  an infected mosquito 
(21, 57–59). The infected DCs secrete proinflammatory cytokines and chemokines, resulting in an influx of  
monocytes into the dermis that can differentiate into DCs and become new targets for DENV replication 
(59). Infected DCs undergo activation and maturation, which is characterized by the upregulation of  mark-
ers, such as CD40, CD80, CD86 and CCR7. Cytokine production (e.g., TNF-α and IL-1β) by DENV-infect-
ed cells can activate bystander DCs, causing them to mature and upregulate CCR7. Other immune stimuli, 
such as defective viral particles or DENV-infected DC-derived exosomes containing viral components (60–
64), could also activate bystander cells. Both infected and bystander DCs are then able to migrate to draining 
lymph nodes and interact with T cells (57). Bystander cells could also have been abortively infected or could 
have captured DENV antigens via phagocytosis of  exosomes containing DENV antigens; those antigens 
would have been missed with the antibody used to measure active replication in our assay. Thus, it is possible 
that bystander cells may still be able to present DENV antigens to T cells in the lymph nodes. On the other 
hand, it is also possible that bystander cells may not have acquired DENV antigens, and their migration 
to the draining lymph nodes may interfere with T cell priming by DENV-infected DCs. The magnitude of  
type I IFN and IP-10 production by DCs may also contribute to the ability of  these DCs to prime T cells in 
the lymph node toward a Th1 response (16). In this way, infection of  DCs with this DENV-4 strain, which 
results in greater production of  IFN-α, IP-10, and IL-12, may be more efficient at skewing the adaptive 
immune response toward a Th1 response compared with infection with this DENV-2 strain.
Altogether, this study illustrates the power of  utilizing CyTOF to examine the complex immune phe-
notypes following virus infection. Indeed, using this technology, we provide insights into the differences 
between serotypes and bystander cells versus infected cells. From our data, we also postulate that different 
DENV strains use different replication strategies to produce a sufficiently high viremia for transmission back 
to the mosquito vector; these differences in replication will also greatly affect innate immune induction in 
the host. Finally, this work may provide a useful framework for investigating emerging viruses, in particular, 
arboviruses, like chikungunya virus and Zika virus, that have caused recent epidemics. Investigating different 
replication strategies used by vector-borne viruses and the consequential immune induction by the host may 
provide insights into different fitness strategies that vector-borne viruses use to remain in circulation.
Methods
Cell lines. Baby hamster kidney (BHK) cells (originally obtained from Sujan Shresta, La Jolla Institute for 
Allergy and Immunology, La Jolla, California, USA) were cultured at 37°C in α-MEM GlutaMAX, sup-
plemented with 10% (v/v) FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, and 10 mM HEPES. These 
tissue culture reagents were purchased from Thermo Fisher Scientific. Aag2 (Aedes aegypti) cells were a 
gift from Raul Andino (University of  California, San Francisco, San Francisco, California, USA) and were 
maintained in Leibovitz’s L-15 media (Thermo Fisher Scientific) supplemented with 8% (v/v) tryptose 
phosphate broth, 2 mM L-glutamine, 0.1 mM MEM nonessential amino acids (Sigma-Aldrich), 100 U/ml 
penicillin, 100 μg/ml streptomycin, and 10% (v/v) FBS (all Thermo Fisher Scientific) at 28°C in a humid-
ified atmosphere without CO2. C6/36 (Aedes albopictus) cells (originally obtained from Jorge Munoz-Jor-
dan, Centers for Disease Control and Prevention, San Juan, Puerto Rico) were maintained in RPMI media 
(Invitrogen) supplemented with 0.15% (m/v) sodium bicarbonate (Sigma-Aldrich), 1X MEM nonessential 
amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, and 10% (v/v) FBS (all from Thermo Fisher 
Scientific) at a 33°C (with 5% CO2) incubator.
All cell lines used herein were tested for the presence of  Mycoplasma using the Mycoalert mycoplasma 
detection kit from Lonza (catalog LT07-118). Cells and virus preparations used in these experiments were 
all Mycoplasma free.
Virus preparations. A prototypic DENV-2 strain belonging to the Asian I genotype (Supplemental Fig-
ure 2) that was isolated from a patient with dengue shock syndrome in Thailand in 1964 (DENV-2 16681) 
(65, 66) and a DENV-4 strain belonging to genotype IIB (Supplemental Figure 1) that was isolated from a 
patient with dengue fever in Indonesia in 1976 (DENV-4 1036) (67) were used in this study (68). DENV-2 
16681 (cDNA) and DENV-4 1036 were initially obtained from Richard Kinney (Arbovirus Disease Branch, 
Centers for Disease Control and Prevention, Fort Collins, Colorado, USA) and underwent minimal sub-
sequent passages in C6/36 cells in our laboratory. These viruses were both grown in C6/36 insect cells for 
7 days as described elsewhere (69). In brief, C6/36 cells were infected with either DENV-2 or DENV-4 
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at MOI of  0.01; 7 days after infection, cell supernatant was collected and stored at –80°C. DENV stock 
titers were determined by limiting-dilution plaque assays on BHK cells as described below. UV-inactivated 
DENV-2 and DENV-4 were prepared by irradiating the virus with a UV lamp for 10 minutes (at 6 inches); 
virus inactivation was confirmed by plaque assay on BHK cells.
The complete genome sequence of  the DENV-4 isolate was obtained by sequencing overlapping 
RT-PCR products (1.0- to 1.5-Kbp length) using viral RNA purified from DCs infected with DENV-4 
as template. A set of  10 primer pairs was designed based on the sequence of  available DENV-4 com-
plete genomes. Each primer included the sequence of  universal primers M13-fwd (GTAAAACGACGGC-
CAGT, forward primers) or M13-rev (CAGGAAACAGCTATGAC, reverse primers) to facilitate sequenc-
ing. High-fidelity RT-PCR was performed using the Superscript III high-fidelity RT-PCR kit (Invitrogen) 
and the conditions recommended by the manufacturer. RT-PCR products were purified from an agarose gel 
and sequenced using universal primers M13-fwd and M13-rev. Finally, the complete genome was manually 
assembled from the overlapping sequences and has been uploaded to GenBank with accession number 
KX812530 (https://www.ncbi.nlm.nih.gov/nuccore/KX812530).
To construct a phylogenetic tree, a selection of  complete genomes of  DENV-4 was downloaded from 
the NIAID Virus Pathogen Database and Analysis Resource (70) through the website (http://www.vipr-
brc.org/). The selection was manually trimmed to contain 57 isolates representative of  the complete genetic 
diversity, and the sequence of  Indonesia 1976 (strain 1036) was included. A consensus neighbor-joining 
phylogenetic tree from 1,000 replicates was obtained using the program Geneious (http://www.geneious.
com/). The tree was visualized using FigTree (Supplemental Figure 1) (available at http://tree.bio.ed.ac.
uk/software/figtree/) and rooted at midpoint for clarity. The genomes used in the alignment were as fol-
lows: Brazil2-2010: JN983813.1; Brazil3-2010: JN559741.2; Venezuela5-2007: HQ332176.1; Venezue-
la4-2007: GQ868644.1; Colombia-2005: GQ868585.1; Venezuela3-2007: HQ332175.1; Venezuela-2007: 
FJ182017.1; Venezuela2-2007: FJ882582.1; Brazil-2010: JQ513333.1; Colombia-2004: GQ868584.1; 
Venezuela-2000: FJ850095.1; Colombia-2001: GQ868579.1; Venezuela-1998: FJ639739.1; USA2-1998: 
EU854296.1;USA-1986: EU854295.1; USA-1999: FJ882599.1; USA2-1996: GQ199882.1; USA-1998: 
FJ882596.1; USA2-1994: GQ199878.1; USA-1996: GQ199881.1; Haiti-2014: KT276273.1; Haiti-1994: 
JF262782.1; USA-1994: GQ199879.1; Dengue_814669: AF326573.1; Senegal-1953: KF907503.1; 
Colombia-1982: GU289913.1; Brazil-1976: JN559740.2; Venezuela-1995: JF262781.1; Indonesia-1976: 
KX812530; Singapore-1995: AY762085.1; New-Caledonia-2009: JQ915089.1; French-Polynesia-2009: 
JQ915082.1; French-Polynesia-2010: JQ915084.1; Indonesia2-2007: KC762697.1; Thailand-2000: 
AY618993.1; China-2010: KP723482.1; Indonesia-2007: KC762696.1; New-Caledonia-2008: JQ915085.1; 
Singapore-2010: JX024758.1; Singapore-2005: GQ398256.1; China-2012: KC333651.1; China-1978: 
FJ196849.1; Cambodia-2008: JN638570.1; Thailand-2001: AY618992.1; Thailand-1991: AY618990.1; 
Cambodia-2002: KF955510.1; Thailand-1977: AY618991.1; Pakistan-2009: KF041260.1; India-2009: 
JQ922560.1; India-1979: JQ922559.1; South-Korea: KP406806.1; Philippines-1956: GQ868594.1; China: 
AF289029.1; China-1990: FJ196850.1; India-1962: JQ922558.1; India-1961: JF262783.1; Thailand-1997: 
AY618988.1; MONKEY-Malaysia-1975: JF262779.1.
Similarly, a consensus neighbor-joining phylogenetic tree of  55 DENV-2 complete genomes was 
made (Supplemental Figure 2). Genomes used in the alignment were as follows: VietNam2/2006: 
EU482654; VietNam-N/A: JQ045677; Thailand/2001: FJ639832; Thailand/1988: DQ181802; N/A-
1996: AF100463; Thailand/1993: AF022439; Thailand/1994: EU726767; Thailand/1979: DQ181805; 
Thailand/1984: DQ181804; Thailand/1974: GU289914; Thailand/1964: GQ868591; DENV-2 
16681-Thailand/1964: U87411.1; USA/2007: JF730050; USA/2010: HQ541799; Colombia/1944: 
EU854293; Cuba/1981: KF704354; Indonesia/1975: GQ398268; Philippines/1996: KF744404; 
USA/2000: EU687222; Puerto Rico/2006: KF955364; USA/1996: EU596486; Venezuela/1991: 
GQ868596; Puerto Rico/1986: KF955363; USA/1989: EU482580; Mexico/2010: KJ189309; Thai-
land/1990: DQ181801; VietNam3/2006: EU482672; China/2010: JX470186; Singapore/2006: 
JN851128; Singapore/2010: KM279579; Taiwan/2002: DQ645553; India/2006: FJ898454; Paki-
stan/2010: KF360005; India/1996: JQ922549; N/A-1999: AF359579; Fiji/1971: HM582101; 
New Caledonia/1972: HM582103; French Polynesia/1973: HM582110; Tonga/1974: HM582111; 
Puerto Rico/1969: JX966380; Puerto Rico/1977: EU056812; Mexico/1992: GQ868590; Mexi-
co/1994: JX966379; Mexico/1983: GQ868588; Colombia/1986: GQ868592; India/1971: JQ922550; 
India/1980: JQ922553; India/1960: JQ922552; Burkina Faso/1980: EF105386; Cote d’Ivoire/1980: 
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EF105381; Senegal/1999: EF105390; Senegal/1970: EF105384; Senegal/1974: EF105385; Nige-
ria/1966: EF105388; Malaysia/1970: EF105379.
DENV titration by plaque assay. DENV infectious particles were titrated by plaque assay using BHK cells 
and a standard protocol (65). BHK cells were seeded in 12-well plates (at 1 × 105 cells/well) and incubated 
overnight at 37°C with 5% CO2. The following day, the medium was removed and serial dilutions of  virus 
supernatants in α-MEM GlutaMAX were added to the wells (150 μl virus inoculum/well). The cells were 
then incubated at 33°C and 5% CO2 for 2 hours. Following this incubation, an overlay consisting of  1% 
low-melting-point Lonza SeaPlaque Agarose in distilled H2O (Thermo Fisher Scientific), 5% FBS, and 45% 
2X MEM (Thermo Fisher Scientific) was added at 1.5 ml/well, and the plates were incubated at 33°C with 
5% CO2 for 7 days. Subsequently, after removing the overlay, the plaques were fixed and visualized with a 
1% crystal violet solution in 20% ethanol for >10 minutes.
Generation of  monocyte-derived DCs. Monocyte-derived DCs were generated from buffy coats of  healthy 
human donors (New York Blood Center) using a standard protocol (16, 17, 25, 71). Briefly, peripheral blood 
mononuclear cells were isolated using Ficoll gradient centrifugation (Histopaque, Sigma-Aldrich). Next, 
CD14+ cells were isolated from the mononuclear fraction using the MACS CD14+ isolation kit (Miltenyi 
Biotech) according to the manufacturer’s instructions. CD14+ cells were then differentiated into naive imma-
ture DCs by incubation in DC media (RPMI medium with 2 mM L-glutamine, 100 U/ml penicillin, 100 
μg/ml streptomycin, and 1 mM sodium pyruvate [Thermo Fisher Scientific]) supplemented with 500 U/
ml human granulocyte-macrophage colony-stimulated factor (GM-CSF) (PeproTech), 1,000 U/ml human 
IL-4 (PeproTech), and 10% (v/v) Hyclone FBS (Thermo Fisher Scientific) for 5 days at 37°C and 5% CO2.
DENV infection of  DCs. After 5 days in culture, donor-matched naive DCs were infected with DENV-2 or 
DENV-4 at an MOI of  0.5 or treated with UV-inactivated virus or DC medium (mock) for 60 minutes at 37°C 
with 5% CO2. After virus adsorption, the virus inoculum was removed following centrifugation at 400 g for 
10 minutes, and the DCs were then maintained in culture at 1 × 106 cells/ml in DC media containing 10% 
FBS at 37°C and 5% CO2 for different time periods, depending on the experiment. For infections with UV-in-
activated DENV, the same volume of  UV-inactivated DENV was added compared with infectious DENV.
DENV infection of  Aag2 cells. Subconfluent Aag2 cells cultured in 24-well plates were washed once in 
PBS 24 hours after seeding and then infected with DENV at an MOI of  0.5 in 200 μl PBS. Following 
a 1-hour incubation at 28°C, the inoculum was removed and cells were washed once in PBS and then 
returned in Aag2 culture media to the 28°C incubator. Supernatants were harvested at indicated time 
points and titrated on BHK cells as previously described.
Multiplex ELISA. The Cytokine Human Magnetic 25-Plex Panel for Luminex Platform (Thermo Fisher 
Scientific) was used according to the manufacturer’s instructions. This kit can detect the following cytokines 
and chemokines: GM-CSF, TNF-α, IL-1β, IL-4, IL-6, MIP-1β, Eotaxin, RANTES, MIG, IL-12 (p40/p70), 
IL-8, IL-17, MIP-1α, IL-10, IL-1RA, IFN-γ, IL-13, MCP-1, IL-7, IL-15, IFN-α, IL-2R, IP-10, IL-5, and IL-2.
The data were acquired on the Luminex 100 System and were analyzed by a standard curve fit, accord-
ing to the manufacturer’s protocol (72). In brief, for each analyte, a 7-point dilution series of  the protein 
standard plus an assay diluent-only background well were run in duplicate. A standard curve was then 
fitted using a weighted 5-parameter logistic function. Protein concentrations of  the unknown samples were 
quantified from the standard curves, and duplicates were averaged for downstream statistical analysis. The 
standard curve modeling was performed in R version 3.2.0 (73).
Flow cytometry. Mock- or DENV-infected DCs were first incubated in Human TruStain FcX (Bioleg-
end), followed by incubation using the Live/Dead Fixable Blue Dead Cell Stain Kit (Thermo Fisher Scien-
tific), according to the manufacturer’s instructions. Cells were then fixed and permeabilized with Cytofix/
Cytoperm (BD Pharmingen) and subsequently stained with anti-DENV NS3 monoclonal antibody E1D8 
(74) (a gift from Eva Harris, University of  California, Berkeley, Berkeley, California, USA) at 10 μg/ml, 
which was directly conjugated with DyLight 488 (Thermo Fisher Scientific). Samples were run on an 
LSRII flow cytometer, available through Mount Sinai’s Flow Cytometry Shared Resource Facility. Data 
analysis was performed with Cytobank software version 5.2.0 (Cytobank Inc.).
CyTOF staining and analysis. All CyTOF reagents were acquired from Fluidigm Inc. unless otherwise 
indicated. All antibodies were either purchased preconjugated from Fluidigm or conjugated and validated 
in-house using MaxPar X8 conjugation kits (Fluidigm Inc.) according to the manufacturer’s instructions. 
Antibody clone numbers are provided in Supplemental Table 1. Viability staining was first performed 
on the mock- or DENV-infected DCs by adding 1 μM Rh103 nucleic acid intercalator directly to the cell 
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culture media at the indicated time point after infection and incubating for 20 minutes at 37°C. Samples 
were then washed in PBS containing 0.1% BSA, blocked with Human TruStain FcX (Biolegend), and 
incubated with a 0.1-micron-filtered cocktail of  titrated MaxPar antibodies against cell surface markers 
(Supplemental Table 1) for 20 minutes at 4°C. The samples were washed, and mock and DENV-infected 
samples were subsequently fixed and barcoded using a Cell-ID 20-Plex Pd barcoding kit with a unique 
barcode ID assigned to each condition and time point. After barcoding, the samples were pooled to min-
imize staining variability, permeabilized using BD Cytofix/Cytoperm (BD Biosciences), and incubated 
with a 0.1-micron-filtered cocktail of  MaxPar antibodies against intracellular antigens (Supplemental 
Table 1) for 20 minutes at 4°C. The samples were then washed, incubated with 0.125 nM Ir nucleic acid 
intercalator to enable cell identification based on DNA content, and stored in PBS containing 2% freshly 
diluted formaldehyde (Electron Microscopy Sciences) until acquisition. Samples collected at the 8, 24, 48, 
and 72 hpi time points were stored and then combined together and acquired simultaneously as a single 
barcoded sample to minimize acquisition batch effects. Immediately prior to acquisition, the barcoded 
samples were washed in diH20 and resuspended at a concentration of  600,000 cells per ml with a 1:20 
dilution of  EQ 4 element beads. Samples were acquired on a CyTOF2 using a SuperSampler fluidics 
system (Victorian Airships) at an event rate of  <350 events/s. Following data acquisition, data were con-
catenated and normalized using the CyTOF2 software. The barcoded samples were then deconvoluted 
using a Matlab-based debarcoding and doublet-filtering application (75), using a stringent Mahalanobis 
distance cutoff  to ensure optimal barcode separation. The data were then uploaded to Cytobank version 
5.2.0 (Cytobank Inc.) for analysis.
The data were analyzed using a combination of  manual gating approaches (Supplemental Figure 
3A), autogating based on 99th percentile baseline thresholding (Figure 2 and Supplemental Figure 3B) 
(36, 37), and viSNE (Figure 3 and Supplemental Figure 7) (35). Manual and automatic gating have 
comparative advantages and disadvantages that could be accentuated by the high dimensionality of  
CyTOF data. Although it is currently the standard method, manual gating may be subject to operator 
bias in choosing thresholds for marker positivity or negativity (76), whereas autogating is not subject 
to such bias, as it specifies a deterministic and perfectly reproducible threshold for each channel. On 
the other hand, the sensitivity and specificity of  autogating may be affected by data quality and certain 
analytical assumptions, such as the unexpected presence of  outlier data that could skew automatically 
calculated thresholds (77), whereas an expert human operator would be able to notice and correct for 
this problem. By utilizing both types of  analyses in this study, the patterns of  cell phenotypes were 
shown to be generally consistent under either method (Supplemental Figure 3B) and therefore robust to 
the choice of  gating technique.
Additionally, viSNE analysis allowed for the visualization of  high-dimensional, single-cell CyTOF data 
in two-dimensional plots (35). With this dimensionality-reducing algorithm, phenotypic changes could be 
appreciated in a coordinated pattern, in which the relative position of  a cell on the plot indicated its general 
phenotype in multidimensional space (35). The staining intensities for the indicated markers were displayed 
as expression level gradients. viSNE plots were generated using all 18 phenotypic markers from the CyTOF 
panel (Supplemental Table 1). DENV E and NS3 proteins were purposefully excluded as clustering param-
eters in order to visualize the distribution of  infection across cellular phenotypes.
Statistics. For data with multiple DC donors, significance was determined using a paired, 2-tailed 
Wilcoxon signed-rank test, which does not assume a normally distributed population. The Benjami-
ni-Hochberg procedure was performed at each time point for each cytokine/chemokine or CyTOF mark-
er to adjust the significance level for multiple comparisons. P ≤ 0.05 after correcting for multiple compar-
isons was considered statistically significant. Wilcoxon signed-rank tests were performed with Prism 7 
GraphPad software, and Benjamini-Hochberg procedures were performed with R version 3.3.0.
Event counts for manually gated CyTOF data were exported from Cytobank Inc. Autogating of  
CyTOF data was performed by setting a threshold at the 99th percentile of  the distribution of  observed 
intensities for each marker at the 8 hpi time point in mock-treated samples (36, 37). This threshold 
was then applied to all other time points and treatments for that donor, which created event counts for 
positive and negative subpopulations. The comparative effects of  infection condition on marker expres-
sion were calculated within each donor as the log10 of  the relative risk for positive marker frequency in 
the live populations extracted at each time point for each marker. Since manual gating and autogating 
strategies were determined to show grossly consistent patterns (Supplemental Figure 3B), autogating 
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was used for more extensive analyses (Figure 2). In these analyses, markers were ordered vertically by 
a hierarchical clustering of  the median log10 relative risks for that marker and time point. Hierarchical 
clustering was performed using the R hclust function using “complete” agglomeration and the Euclid-
ean distance between row vectors (73). Statistical significance was determined using a 2-sided Fisher’s 
exact test at a threshold of  α = 10–5 with Bonferroni correction for multiple testing, similar to previous 
analyses of  flow cytometry counts (78). Statistical analyses for Figure 2 were performed with R version 
3.2.2 (73). Autogating was implemented using the flowCore (79) and flowStats (80) R packages from 
Bioconductor (versions 1.36.9 and 3.28.1, respectively).
Study approval. Primary human cells used in this work were obtained from buffy coats from the New 
York Blood Center and were deidentified prior to distribution by the New York Blood Center. As such, these 
samples are considered to be nonhuman subjects and do not require institutional review board approval.
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